Tadashi YASUDA
(Kobe City Medical Center General Hospital, Department of Orthopaedic Surgery, Japan)
Kazuhiro MATSUNAGA
(Kobe City Medical Center General Hospital, Department of Orthopaedic Surgery, Japan)
Takumi HASHIMURA
(Kobe City Medical Center General Hospital, Department of Orthopaedic Surgery, Japan)
Yoshihiro TSUKAMOTO
(Kobe City Medical Center General Hospital, Department of Orthopaedic Surgery, Japan)
Tatsuya SUEYOSHI
(Kobe City Medical Center General Hospital, Department of Orthopaedic Surgery, Japan)
Satoshi OTA
(Kobe City Medical Center General Hospital, Department of Orthopaedic Surgery, Japan)
Satoshi FUJITA
(Kobe City Medical Center General Hospital, Department of Orthopaedic Surgery, Japan)
Eijiro ONISHI
(Kobe City Medical Center General Hospital, Department of Orthopaedic Surgery, Japan)
Yıl: 2021Cilt: 8Sayı: 2ISSN: 2147-9720 / 2148-4279Sayfa Aralığı: 57 - 61İngilizce

14 0
Bone turnover markers in the early stage of rapidly progressive osteoarthritis of the hip
Objective: Previous reports have demonstrated that patients with end-stage rapidly progressive osteoarthritis of the hip (RPOH) show significantly higher serum levels of bone turnover markers thanthose with osteoarthritis (OA). However, the characteristics of bone turnover markers in the early stageof RPOH remain unclear. This study aimed to elucidate the association of bone turnover markers withdisease progression in the early stage of RPOH.Methods: This study included 29 postmenopausal female patients with joint space narrowing >2 mmdemonstrated on a series of radiographs and computed tomography within 1 year following the onset of hip pain. The study also included 9 postmenopausal female patients with hip OA secondary todevelopmental dysplasia showing femoral head destruction. Cortical thickness index (CTI) associatedwith bone mineral density of the hip was analyzed. Serum concentrations of tartrate-resistant acidphosphatase-5b (TRACP-5b) and bone alkaline phosphatase (BAP) were evaluated.Results: RPOH was classified into two types on the basis of the absence (type 1, n=13) or presence(type 2, n=16) of subsequent destruction of the femoral head within 1 year following disease onset.TRACP-5b and BAP significantly increased in RPOH type 2 compared with type 1 and OA. Receiver operating characteristic curve analyses indicated that TRACP-5b and BAP could differentiate RPOH type2 from type 1 within 1 year following the onset. CTI showed no difference among the RPOH types 1and 2 and OA.Conclusion: High serum levels of bone turnover markers may be associated with destruction of thefemoral head in the early stage of RPOH.
DergiAraştırma MakalesiErişime Açık
  • 1. Bock GW, Garcia A, Weisman MH, Major PA, Lyttle D, Haghighi P, et al. Rapidly destructive hip disease: Clinical and imaging abnormalities. Radiology 1993; 186: 461-6.
  • 2. Lequesne M. [Rapid destructive coxarthritis] (In French). Rheumatologie 1970; 2: 51-63.
  • 3. Watanabe W, Sato K, Itoi E, Yang K, Watanabe H. Posterior pelvic tilt in patients with decreased lumbar lordosis decreases acetabular femoral head covering. Orthopedics 2002; 25: 321-4.
  • 4. Masuhara K, Nakai T, Yamaguchi K, Yamasaki S, Sasaguri Y. Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip. Arthritis Rheum 2002; 46: 2625-31.
  • 5. Sugano N, Ohzono K, Nishii T, Sakai T, Haraguchi K, Yoshikawa H, et al. Early MRI findings of rapidly destructive coxopathy. Magn Reson Imaging 2001; 19: 47-50.
  • 6. Zazgyva A, Gurzu S, Gergely I, Jung I, Roman CO, Pop TS. Clinico-radiological diagnosis and grading of rapidly progressive osteoarthritis of the hip. Medicine (Baltimore) 2017; 96: e6395.
  • 7. Yasuda T, Matsunaga K, Hashimura T, Tsukamoto Y, Sueyoshi T, Ota S, et al. Characterization of rapidly progressive osteoarthritis of the hip in its early stage. Eur J Rheumatol 2020; 7: 130-4.
  • 8. Ogawa K, Mawatari M, Komine M, Shigematsu M, Kitajima M, Kukita A, et al. Mature and activated osteoclasts exist in the synovium of rapidly destructive coxarthrosis. J Bone Miner Metab 2007; 25: 354-60.
  • 9. Yamaguchi R, Yamamoto T, Motomura G, Ikemura S, Iwasaki K, Zhao G, et al. Bone and cartilage metabolism markers in synovial fluid of the hip joint with secondary osteoarthritis. Rheumatology (Oxford) 2014; 53: 2191-5.
  • 10. Abe H, Sakai T, Ogawa T, Takao M, Nishii T, Nakamura N, et al. Characteristics of bone turnover markers in rapidly destructive coxopathy. J Bone Miner Metab 2017; 35: 412-8.
  • 11. Yeung Y, Chiu KY, Yau WP, Tang WM, Cheung WY, Ng TP. Assessment of the proximal femoral morphology using plain radiograph-can it predict the bone quality? J Arthroplasty 2006; 21: 508- 13.
  • 12. Baumgärtner R, Heeren N, Quast D, Babst R, Brunner A. Is the cortical thickness index a valid parameter to assess bone mineral density in geriatric patients with hip fractures? Arch Orthop Trauma Surg 2015; 135: 805-10.
  • 13. Nguyen BN, Hoshino H, Togawa D, Matsuyama Y. Cortical thickness index of the proximal femur: A radiographic parameter for preliminary assessment of bone mineral density and osteoporosis status in the age 50 years and over population. Clin Orthop Surg 2018; 10: 149-56.
  • 14. Postel M, Kerboull M. Total prosthetic replacement in rapidly destructive arthrosis of the hip joint. Clin Orthop Relat Res 1970; 72: 138-44.
  • 15. Pivec R, Johnson AJ, Harwin SF, Mont MA. Differentiation, diagnosis, and treatment of osteoarthritis, osteonecrosis, and rapidly progressive osteoarthritis. Orthopedics 2013; 36: 118-25.
  • 16. Tang C, Liu Y, Qin H, Li X, Guo W, Li J, et al. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients. Clin Chim Acta 2013; 426: 102-7.
  • 17. Richette P, Vicaut E, de Vernejoul MC, Orcel P, Bardin T. Bone mineral density in patients with rapidly destructive or common hip osteoarthritis. Clin Exp Rheumatol 2009; 27: 337-9.
  • 18. Okano K, Aoyagi K, Enomoto H, Osaki M, Chiba K, Yamaguchi K. Bone mineral density in patients with destructive arthrosis of the hip joint. J Bone Miner Metab 2014; 32: 312-6.
  • 19. Dewhirst FE, Stashenko PP, Mole JE, Tsurumachi T. Purification and partial sequence of human osteoclast-activating factor: Identity with interleukin 1 beta. J Immunol 1985; 135: 2562-8.
  • 20. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: Modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000; 275: 768-75.
  • 21. Tamai M, Sagawa K, Kawabata R, Inoue A, Itoh K. Production of IL-6 by T cells from the femoral head of patients with rapidly destructive coxopathy (RDC). Clin Exp Immunol 1996; 103: 506-13.
  • 22. Abe H, Sakai T, Ando W, Takao M, Nishii T, Nakamura N, et al. Synovial joint fluid cytokine levels in hip disease. Rheumatology (Oxford) 2014; 53: 165-72.
  • 23. Kim N, Kadono Y, Takami M, Lee J, Lee SH, Okada F, et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med 2005; 202: 589-95.
  • 24. Yokota K, Sato K, Miyazaki T, Kitaura H, Kayama H, Miyoshi F, et al. Combination of tumor necrosis factor α and interleukin-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in vivo. Arthritis Rheumatol 2014; 66: 121-9.
  • 25. Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, Suva LJ. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 2003; 33: 28-37.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.